Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review

Date: July 5, 2019
Pages: 53
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: C8D8B52275EEN
Leaflet:

Download PDF Leaflet

Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review
Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, neurological, ophthalmic, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, US, Canada, South Africa and major regulated and emerging markets among others. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd Key Recent Developments

Jun 21,2019: Cipla: Resignation of Mr. Peter Lankau as Independent Director of the Company
Jun 10,2019: Cipla: Closure Of USFDA inspection at Kurkumbh Manufacturing Facility
May 22,2019: Cipla reports Q4 and FY19 results
May 17,2019: USFDA post-approval inspection completed at Cipla's Indore manufacturing facility
Apr 22,2019: Cipla names Dr. Raju Mistry as Global Chief People Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Cipla Ltd - Key Facts
Cipla Ltd - Key Employees
Cipla Ltd - Key Employee Biographies
Cipla Ltd - Major Products and Services
Cipla Ltd - History
Cipla Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Cipla Ltd - Business Description
Business Segment: New Ventures
Overview
Performance
Business Segment: Pharmaceuticals
Overview
Performance
R&D Overview
Cipla Ltd - Corporate Strategy
Cipla Ltd - SWOT Analysis
SWOT Analysis - Overview
Cipla Ltd - Strengths
Cipla Ltd - Weaknesses
Cipla Ltd - Opportunities
Cipla Ltd - Threats
Cipla Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Cipla Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 21, 2019: Cipla: Resignation of Mr. Peter Lankau as Independent Director of the Company
Jun 10, 2019: Cipla: Closure Of USFDA inspection at Kurkumbh Manufacturing Facility
May 22, 2019: Cipla reports Q4 and FY19 results
May 17, 2019: USFDA post-approval inspection completed at Cipla's Indore manufacturing facility
Apr 22, 2019: Cipla names Dr. Raju Mistry as Global Chief People Officer
Apr 17, 2019: Pulmatrix and Cipla collaborate to develop asthma drug
Mar 31, 2019: Cipla: Product specific pre-approval (PAI) and Good Manufacturing Practices (GMP) inspection at its Kurkumbh plant
Feb 18, 2019: Cipla and Wellthy Therapeutics announce partnership to offer digital therapeutics for diabetes and cardiovascular diseases
Oct 04, 2018: Cipla:Inspection by the United States Food and Drug Administration (USFDA) at the Goa manufacturing facility
Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Cipla Ltd, Key Facts
Cipla Ltd, Key Employees
Cipla Ltd, Key Employee Biographies
Cipla Ltd, Major Products and Services
Cipla Ltd, History
Cipla Ltd, Subsidiaries
Cipla Ltd, Key Competitors
Cipla Ltd, Ratios based on current share price
Cipla Ltd, Annual Ratios
Cipla Ltd, Annual Ratios (Cont...1)
Cipla Ltd, Annual Ratios (Cont...2)
Cipla Ltd, Interim Ratios
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Cipla Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Cipla Ltd, Performance Chart (2015 - 2019)
Cipla Ltd, Ratio Charts
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Alembic Limited
Dr. Reddy's Laboratories Ltd
Lupin Ltd
Aurobindo Pharma Ltd
Sun Pharmaceutical Industries Ltd
Biocon Ltd
Cadila Healthcare Ltd
Torrent Pharmaceuticals Ltd
Skip to top


Ask Your Question

Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: